Renaissance Capital logo

Corindus Vascular Robotics Priced, NYSE American: CVRS

Sells robotic systems that aid stent placement during coronary angioplasties.

Industry: Health Care

First Day Return: +5.3%

Industry: Health Care

We design, manufacture and sell precision vascular robotic-assisted systems for use in interventional vascular procedures,the CorPath System. Our first and current product, the CorPath 200 System, is the only vascular robotic system cleared by the FDA to bring precision and accuracy to stent placement in percutaneous coronary intervention procedures. While we are initially cleared for and are targeting PCI procedures, we believe our technology platform has the capability to be developed in the future for other segments of the vascular market, including peripheral vascular, neurointerventional and other more complex cardiac interventions such as structural heart. As of March 31, 2015, we have installed 26 CorPath Systems in hospitals in the U.S. and two CorPath Systems in hospitals outside of the U.S.
more less
IPO Data
IPO File Date 05/11/2015
Offer Price $3.80
Price Range $3.80 - $3.80
Offer Shares (mm) 11.0
Deal Size ($mm) $42
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 05/28/2015
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $42
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Waltham, MA, United States
Founded 2011
Employees at IPO 68
Website www.corindus.com

Corindus Vascular Robotics (CVRS) Performance